ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.
- Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.
- These changes lead to high pulmonary arterial pressure, right heart strain, and ultimately, right heart failure and death.
- Altavant is currently testing this mechanism of action in ELEVATE 2, a proof-of-concept Phase 2 study of rodatristat ethyl in patients with PAH.
- Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor in Phase 2 development for patients with pulmonary arterial hypertension.